September 28, 2021

New Glioma Stem Cell-Related Target Identified for Potential Treatment of Glioblastoma

Inhibition of DNA-PK suppresses tumor growth in preclinical models

21-CCC-2251724 cancer-stem-cells_650x450

A Cleveland Clinic-led research team has defined a new mechanism that contributes to the lethality of glioblastoma. The findings, published recently in Science Translational Medicine, focus on glioma stem cells, a particularly dangerous subset of cancer cells that can self-renew and promote tumor growth and resistance to conventional therapies.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Previous research has shown that the SOX2 protein plays an important role in maintaining the disease-driving properties of glioma stem cells. In the new study, Shideng Bao, PhD, and collaborators discovered that another component, DNA-dependent protein kinase (DNA-PK), is also involved. According to their findings, DNA-PK critically controls the stability of SOX2 to maintain glioma stem cells in glioblastoma.

“Our preclinical findings indicate that DNA-PK is a promising new target for disrupting the pro-tumor properties of glioma stem cells to improve glioblastoma treatment,” says Dr. Bao, research staff in the Department of Cancer Biology in Cleveland Clinic’s Lerner Research Institute and Director of its Center for Cancer Stem Cell Research.

How DNA-PK maintains glioma stem cells to drive glioblastoma growth

The researchers found that DNA-PK actually modifies the SOX2 protein through phosphorylation, which stabilizes and prevents SOX2 degradation. It is this stable form of SOX2 that helps maintain the self-renewing and pro-tumor characteristics of glioma stem cells.

One of the defining characteristics of glioma stem cells is their resemblance to neural stem cells, Dr. Bao explains. Similar to neural stem cells, glioma stem cells are poorly differentiated or completely undifferentiated, giving them the capacity to self-replicate and to differentiate into a variety of specialized brain cells.

Advertisement

“These characteristics of glioma stem cells, along with their ability to invade normal brain tissue, make them major drivers of disease progression and therapeutic resistance,” Dr. Bao says. “Therefore, eliminating them or inducing their differentiation may improve therapeutic efficacy for glioblastoma.”

Notably, the researchers found that targeting DNA-PK promotes glioma stem cell differentiation, leading to inhibition of tumor growth and increased sensitivity to radiotherapy in mice.

Accelerating differentiation holds promise to slow disease

Radiation and chemotherapy agents such as etoposide and temozolomide work by damaging DNA in cancer cells. Dr. Bao’s team found that this DNA damage caused the DNA-PK/SOX2 protein complex to separate. As a result, the SOX2 protein degraded, helping to accelerate glioma stem cell differentiation. In other models, the researchers inhibited DNA-PK activity by its specific inhibitor or disrupted DNA-PK expression, which directly resulted in SOX2 degradation and glioma stem cell differentiation.

“We found that pharmacologically inhibiting DNA-PK potently promoted glioma stem cell differentiation, thereby preventing or reducing the cells’ capacity to self-replicate and suppressing glioma stem cell-driven tumor growth,” Dr. Bao notes. “Because glioma stem cells are much more resistant to radiation than differentiated glioma cells, targeting DNA-PK to induce glioma stem cell differentiation sensitized glioblastoma to radiation in preclinical models and improved the therapeutic efficacy.”

Advertisement

Given the beneficial effects in animal models, the researchers believe that targeting DNA-PK alone or in combination with other therapies, such as radiation, for treating glioblastoma is worthy of future investigation in clinical trials.

The research reported here was supported in part by the National Cancer Institute and the National Institute of Neurological Disorders and Stroke.

Related Articles

19-DDI-6059-IBD-CQD
October 12, 2023
Researchers Identify Promising Compound for IBD Treatment

Cleveland Clinic and Johns Hopkins collaboration could help meet need for new therapies

Zika-mosquito-650×450
October 4, 2023
Discovering the Clever Way that Flaviviruses Boost Their Own Replication

Cleveland Clinic researchers’ finding paves the way for new antiviral approaches

23-NEU-4202909-CQD-Hero-650×450
September 20, 2023
Pairing Deep Learning With Wide-Field Microscopy to Refine Study of Brain Tissue

Multicenter collaboration aims to facilitate tracking of neurological activity deep within tissue

23-CCC-3906442 MCEMP1 asthma research 650×450
May 25, 2023
Research Links Immune Cell Receptors to Asthma, Inflammatory Lung Disease

Findings illuminate MCEMP1 protein’s role in severe inflammation

news_1672953098
February 7, 2023
Research Into How Cells ‘Self-Destruct’ Maps Out Body’s Defenses Against Viruses

Anti-viral immunity identified a novel mechanism in necroptosis

LRI_2875909_04-21-22_Ted Ross
October 5, 2022
Where We’re Headed with Vaccine Research: A Conversation with Ted Ross, PhD

Cleveland Clinic’s new Global Director of Vaccine Development outlines plans, priorities

650×450-COVID-research
July 8, 2022
Research Aims to Prevent Future Pandemics

Collaborative involving Cleveland Clinic investigators focuses on antiviral drug development

MED_Zoldsey_2677360
May 11, 2022
New Research Collaborative Aims to Close Minority Health Disparities

Cleveland Clinic Latino Epidemiology Cohort focuses on underrepresented communities in biomedical research

Ad